TC Biopharm (Holdings) Plc (TCBPY)

TC Biopharm (Holdings) Income Statement

Financials in millions GBP. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	-	-	3.84	1.98	1.98
Revenue Growth (YoY)	-	-	94.30%	-	-42.26%
Gross Profit	-	-	3.84	1.98	1.98
Selling, General & Admin	7.4	6.47	8.34	3.11	2.21
Research & Development	5.37	7.77	7.59	6.16	6.68
Other Operating Expenses	0.05	-	-	-	-0.02
Operating Expenses	12.82	14.24	15.93	9.27	8.87
Operating Income	-12.82	-14.24	-12.08	-7.29	-6.89
Interest Expense	-	-0.08	-6.75	-3.44	-0.29
Interest & Investment Income	-	-	-	0	0
Currency Exchange Gain (Loss)	-	-0.08	-0.12	-0.08	-
Other Non Operating Income (Expenses)	0.01	8.05	16.06	-4.18	-
EBT Excluding Unusual Items	-12.81	-6.35	-2.89	-14.99	-7.18
Other Unusual Items	-	-0.65	-0.14	0.01	0.55
Pretax Income	-12.81	-7	-3.03	-14.98	-6.63
Income Tax Expense	-0.65	-1.09	-1.72	-1.41	-1.17
Net Income	-12.15	-5.91	-1.31	-13.58	-5.46
Net Income to Common	-12.15	-5.91	-1.31	-13.58	-5.46
Shares Outstanding (Basic)	0	-	-	-	-
Shares Outstanding (Diluted)	0	-	-	-	-
EPS (Basic)	-128.79	-	-	-	-
EPS (Diluted)	-128.79	-	-	-	-
Free Cash Flow	-12.63	-10.66	-15.53	-5.6	-3.47
Free Cash Flow Per Share	-133.85	-	-	-	-
Gross Margin	-	-	100.00%	100.00%	100.00%
Operating Margin	-	-	-314.32%	-368.28%	-348.05%
Profit Margin	-	-	-34.17%	-686.12%	-275.84%
Free Cash Flow Margin	-	-	-404.03%	-283.07%	-175.21%
EBITDA	-12.39	-13.61	-11.31	-6.48	-6.01
EBITDA Margin	-	-	-294.30%	-	-
D&A For EBITDA	0.43	0.63	0.77	0.81	0.88
EBIT	-12.82	-14.24	-12.08	-7.29	-6.89

Source: S&P Global Market Intelligence. Standard template. Financial Sources.